Combination of A 5-HT(1) Receptor Agonist and an Alpha-2-Delta Ligand for the Treatment of Migraine
AssigneePfizer Inc.
InventorsJayasena Hettiarachchi, Iradi Reza, Carolyn Sikes
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination of a 5-HT1B, 5-HT1D or 5-HT1F agonist and an alpha-2-delta ligand. Such a combination is useful in the treatment of pain, particularly the pain arising from migraine.
Claims13
A combination of a 5-HT1B, 5-HT1D or 5-HT1F agonist and an alpha-2-delta ligand.
(canceled)
A method of treating pain comprising administering simultaneously, sequentially or separately, to a mammal in need of such treatment, an effective amount of a 5-HT1B, 5-HT1D or 5-HT1F agonist and an alpha-2-delta ligand.
A kit comprising a 5-HT1B, 5-HT1D or 5-HT1F receptor agonist, an alpha-2-delta ligand and means for containing said compounds.
Dependencies are inferred from the claim text.